Skip to main content
. Author manuscript; available in PMC: 2017 Jun 22.
Published in final edited form as: Lab Invest. 2016 Aug 29;96(11):1147–1155. doi: 10.1038/labinvest.2016.93

Figure 5.

Figure 5

Intracellular cAMP levels were measured in: (a) small (white bar) and large cholangiocytes (black bar) and (b) also in H69 (white bar) and in LCDE (black bar) treated with 0.2% BSA (basal) vasopressin (100 μg/ml) in the absence or presence of Tolvaptan (100 μg) or OPC-31260 (100 μg). Vasopressin significantly increased the intracellular levels of cAMP mainly in small cholangiocytes, H69 and LCDE. Effects were blocked by preincubation with the two inhibitors, Tolvaptan and OPC-31260. Data are expressed as mean ± s.d. of six experiments. *P<0.05 vs its corresponding basal value, #P<0.05 vs its corresponding vasopressin treatment.